NEW YORK – The US Patent Trial and Appeals Board (PTAB) has invalidated a patent held by 10x Genomics, dealing a blow to the firm's patent infringement lawsuit against single-cell sequencing competitor Parse Biosciences.

纽约——美国专利审判和上诉委员会（PTAB）宣布10x Genomics持有的一项专利无效，这对该公司针对单细胞测序竞争对手Parse Biosciences的专利侵权诉讼构成了打击。

In a judgment issued Tuesday, the PTAB determined that all six claims of US Patent No. 10,155,981, 'Methods for analyzing nucleic acids from single cells,' were unpatentable. Parse had triggered an inter partes review of the patent after 10x used it to sue Parse in 2022. Parse successfully argued that a 2007 paper in Biochemical Genetics and a 2010 international patent filed by Illumina anticipated the claimed inventions.

在周二发布的一项判决中，PTAB认定，美国专利第10155981号“单细胞核酸分析方法”的所有六项权利要求均不可获得专利。2022年，10倍公司用Parse起诉Parse后，Parse引发了各方对该专利的审查。Parse成功地辩称，Illumina于2007年在《生化遗传学》上发表的一篇论文和2010年提交的一项国际专利预期了这些要求保护的发明。

.

.

In the judgment, the PTAB noted that the Illumina patent 'was the basis of multiple rejections by the [US Patent and Trademark] Office in the application that matured into '981, as well as '981's parent.' A US patent application based on the 2007 paper was also 'raised by the Office and substantively discussed as the basis for a potential rejection.'.

在判决中，PTAB指出，Illumina专利“是[美国专利和商标]局在981年到期的申请中多次拒绝的基础，也是981年父母多次拒绝的基础。”基于2007年论文的美国专利申请也“由该办公室提出，并作为潜在拒绝的基础进行了实质性讨论”。

'We are pleased by the PTAB decision to invalidate all the claims in this patent asserted by 10x against Parse,' Alex Rosenberg, cofounder and CEO of Parse Biosciences, said in a statement. 'Parse offers a fundamentally differentiated solution. … The recent decision prioritizes innovation and is a win for the research community.'.

Parse Biosciences联合创始人兼首席执行官亚历克斯·罗森博格（AlexRosenberg）在一份声明中说，我们很高兴PTAB决定使该专利中所有针对Parse的主张无效Parse提供了一个根本不同的解决方案…最近的决定优先考虑创新，是研究界的胜利。”。

'We disagree with the PTAB decision and plan to appeal,' a 10x spokesperson said in an email.

“我们不同意PTAB的决定，并计划上诉，”10x发言人在一封电子邮件中说。

The US Patent and Trademark Office awarded the '981 patent, which listed Nobel laureate Sydney Brenner among its inventors, to 10x in 2018. 10x has alleged that Parse's Evercode WT product also infringes its US Patent No. 10,697,013 and No. 10,240,197, also titled 'Methods for analyzing nucleic acids from single cells,' from the same set of inventors.

2018年，美国专利商标局授予了981年专利，将诺贝尔奖获得者悉尼·布伦纳列为其发明者之一，授予率为10倍。10x指控Parse的Evercode WT产品也侵犯了同一组发明人的美国专利号10697013和10240197，也被称为“单细胞核酸分析方法”。

The PTAB has instituted inter partes review of those patents, as well..

PTAB也对这些专利进行了跨部门审查。。

In a 2019 lawsuit, 10x alleged that Bio-Rad Laboratories subsidiary Celsee's products infringed the '981 patent. The firms settled all litigation and signed a global cross-licensing agreement in 2021.

在2019年的一场诉讼中，10x指控Bio-Rad Laboratories子公司Celsee的产品侵犯了981年的专利。两家公司解决了所有诉讼，并于2021年签署了全球交叉许可协议。

In Wednesday afternoon trading on the Nasdaq, shares of 10x were up 6 percent at $22.65.

周三下午在纳斯达克的交易中，股价上涨了6%，达到22.65美元。